Integrated Diagnostics (LON:IDHC) Stock Price Down 3.4% - What's Next?

Key Points

• Integrated Diagnostics experienced a stock price drop of 3.4%, trading as low as GBX 0.54 ($0.01) recently, with a significantly reduced trading volume of only 44,089 shares.
• The company boasts a market capitalization of £3.26 million and a low P/E ratio of 0.31, indicating potential value but also associated risks.
• Integrated Diagnostics is a leading diagnostics provider in the Middle East and Africa, with key brands operating in several countries including Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan.

Integrated Diagnostics Holdings plc (LON:IDHC - )'s stock price fell 3.4% on Thursday . The company traded as low as GBX 0.54 ($0.01) and last traded at GBX 0.56 ($0.01). 44,089 shares changed hands during trading, a decline of 88% from the average session volume of 362,772 shares. The stock had previously closed at GBX 0.58 ($0.01).

Integrated Diagnostics Stock Performance

The company has a quick ratio of 0.75, a current ratio of 1.59 and a debt-to-equity ratio of 45.72. The company has a market cap of £3.26 million, a PE ratio of 0.31, a P/E/G ratio of 7.65 and a beta of 0.59. The stock's 50 day simple moving average is GBX 0.45 and its two-hundred day simple moving average is GBX 0.38.

Integrated Diagnostics Company Profile

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.